Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Giuseppa Careddu"'
Autor:
Carmelo Carlo-Stella, Antonio Sica, Paola Allavena, Armando Santoro, Luca Castagna, Swaroop Vakkalanka, Srikant Viswanadha, Akihiro Maeda, Francesca M. Consonni, Simone Serio, Giuseppa Careddu, Silvia L. Locatelli
Purpose:Tumor-associated macrophages (TAMs) and the hyperactivation of the PI3K/AKT pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome. Because the δ and γ isoforms of PI3K are overexpressed in Hodgkin/Reed–St
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7d9f22de652aa8ae7e09461e47760a
https://doi.org/10.1158/1078-0432.c.6526757
https://doi.org/10.1158/1078-0432.c.6526757
Autor:
Silvia L. Locatelli, Armando Santoro, Simone Serio, Akihiro Maeda, Paola Allavena, Francesca Maria Consonni, Giuseppa Careddu, Antonio Sica, Swaroop Vakkalanka, Carmelo Carlo-Stella, Srikant Viswanadha, Luca Castagna
Publikováno v:
Clinical Cancer Research. 25:1098-1112
Purpose: Tumor-associated macrophages (TAMs) and the hyperactivation of the PI3K/AKT pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome. Because the δ and γ isoforms of PI3K are overexpressed in Hodgkin/Reed–S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dfa61f84218fce2c1c2e4ab8b68a596
https://doi.org/10.1158/1078-0432.ccr-18-1133
https://doi.org/10.1158/1078-0432.ccr-18-1133
Autor:
Marina Pierdominici, Elena Ortona, Barbara Ascione, Carmelo Carlo-Stella, Walter Malorni, Paola Matarrese, Giuseppa Careddu, Antonella Tinari, Mario Patrizio, Laura Ciarlo, Silvia L. Locatelli, Angela Maselli
Publikováno v:
Oncotarget
// Marina Pierdominici 1, * , Angela Maselli 2, * , Silvia L. Locatelli 3 , Laura Ciarlo 2 , Giuseppa Careddu 3 , Mario Patrizio 2 , Barbara Ascione 2 , Antonella Tinari 4 , Carmelo Carlo-Stella 3 , Walter Malorni 2 , Paola Matarrese 2, ** , Elena Or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72aa8ea75d701d4632128154b5278fb6
http://europepmc.org/articles/PMC5352419
http://europepmc.org/articles/PMC5352419
Autor:
Carmelo Carlo-Stella, Giorgio Inghirami, Peter Sportelli, Armando Santoro, Silvia L. Locatelli, Luca Castagna, Giuseppa Careddu
Publikováno v:
Leukemia. 30:2402-2405
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7fd606c10d563b554b21ea65cfc27ee
https://doi.org/10.1038/leu.2016.224
https://doi.org/10.1038/leu.2016.224
Autor:
Valeria Spina, Giuseppa Careddu, Stefan Hohaus, Armando Santoro, Margarita Kirienko, Federica De Paoli, Carmelo Carlo-Stella, Alessio Bruscaggin, Massimo Magagnoli, Fabrizio Marino, Arturo Chiti, Silvia L. Locatelli, Marcello Rodari, Lucia Morello, Eleonora Calabretta, Martina Di Trani, Davide Rossi, Vanessa Cristaldi, Ettore Rizzo, Francesca Ricci
Publikováno v:
Blood. 134:131-131
Introduction: The programmed cell death 1 (PD-1) monoclonal antibodies (MoAbs) nivolumab and pembrolizumab induce response rates exceeding 70% in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The lack of response to PD-1 MoAbs, and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54a57c70bd0be003da7063d9fd86999c
https://doi.org/10.1182/blood-2019-131096
https://doi.org/10.1182/blood-2019-131096
Autor:
Armando Santoro, Silvia L. Locatelli, Giuliano Giuseppe Stirparo, Carmelo Carlo-Stella, Giuseppa Careddu, Luca Castagna
Publikováno v:
Scientific Reports
PI3K/AKT and RAF/MEK/ERK pathways are constitutively activated in Hodgkin lymphoma (HL) patients, thus representing attractive therapeutic targets. Here we report that the PI3K/ERK dual inhibitor AEZS-136 induced significant cell proliferation inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::618b55e5477ca36403baef1af9b6e90c
https://pubmed.ncbi.nlm.nih.gov/27767172
https://pubmed.ncbi.nlm.nih.gov/27767172
Autor:
Carmelo Carlo-Stella, Simone Serio, Francesca Maria Consonni, Armando Santoro, Luca Castagna, Silvia L. Locatelli, Swaroop Vakkalanka, Giuseppa Careddu, Srikant Viswanadha
Publikováno v:
Blood. 128:45-45
INTRODUCTION: Primary refractory and early-relapsed patients with Hodgkin lymphoma (HL) experience poor responses to salvage chemotherapy and dismal long-term disease control. Therefore, they represent an unmet medical need urgently requiring not onl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e0244947a05d82cbfec74a9b82e275b
https://doi.org/10.1182/blood.v128.22.45.45
https://doi.org/10.1182/blood.v128.22.45.45
Autor:
Srikant Viswanadha, Carmelo Carlo-Stella, Silvia L. Locatelli, Armando Chierchia, Luca Castagna, Swaroop Vakkalanka, Armando Santoro, Giuseppa Careddu
Publikováno v:
Blood. 126:1561-1561
INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL). Activation of this pathway is critical for transformation and also for the angiogenic switch in malignant cells. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb30c892d65466d01e399f5db869de01
https://doi.org/10.1182/blood.v126.23.1561.1561
https://doi.org/10.1182/blood.v126.23.1561.1561
Autor:
Carmelo Carlo-Stella, Srikant Viswanadha, Swaroop Vakkalanka, Luca Castagna, Giuseppa Careddu, Armando Santoro, Silvia L. Locatelli
Publikováno v:
Cancer Research. 75:2420-2420
Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL). Expression of the δ and γ isoforms of PI3K is restricted to cells of the hematopoietic system, suggesting that RP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c125a4e237db084a9c707c108bf0eca
https://doi.org/10.1158/1538-7445.am2015-2420
https://doi.org/10.1158/1538-7445.am2015-2420
Autor:
Ada Koschorke, Monica Balzarotti, Silvia L. Locatelli, Carmelo Carlo-Stella, Armando Santoro, Luca Castagna, Giuliano G Stirparo, Roberto Papait, Giuseppa Careddu
Publikováno v:
Blood. 124:2253-2253
INTRODUCTION: Lenalidomide monotherapy exerts clinical activity in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) with better response rate and progression-free survival being recorded in activated B-cell-like (ABC) rather than germinal ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80377c03504e3a6cc42d91657f51d90c
https://doi.org/10.1182/blood.v124.21.2253.2253
https://doi.org/10.1182/blood.v124.21.2253.2253